| Name | Title | Contact Details |
|---|
Cure Alzheimers Fund is a non-profit organization that funds targeted research with the highest probability of preventing, slowing, or reversing Alzheimers disease.
WellBe Senior Medical specializes in caring for patients with complex, chronic conditions, whose health is changing with age. As geriatric specialists, we have decades of experience serving these patients. We are committed to providing personal, Complete Care™ at home or anywhere our patients are, and our care team works together with patients, caregivers and physicians to nurture all aspects of health. The care we provide is sponsored by health plans and free to our patients.
Professional Management, Inc. (PMI) specializes in AR management, billing, and consulting services for physicians. We believe that the benefits of choosing PMI to manage your accounts receivable will result in selecting a billing agent that: Has
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Desert Senita Community Health Center is a Ajo, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.